{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"tesamorelin-statins","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-statins/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/tesamorelin-statins/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-statins/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-statins/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-statins/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-statins/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/tesamorelin-statins/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"tesamorelin-statins","title":"Tesamorelin and Statins: Evidence on Visceral Fat, Lipids, and Repair Pathways","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:42:26.614Z","body_excerpt":"## What's breaking down if you have Statins\n\nStatins primarily manage blood lipids by inhibiting HMG-CoA reductase in the liver. This reduces circulating cholesterol and lowers cardiovascular risk in many people. For readers exploring this cross, the relevant layers include potential muscle effects in a subset of users, debated impacts on glucose handling or cognition in sensitive individuals, and ongoing visceral fat accumulation that statins do not directly target. \n\nIf your profile includes excess visceral adipose tissue, that tissue releases inflammatory signals and free fatty acids that can worsen metabolic stress. Statins address one pathway (hepatic cholesterol synthesis) but leave visceral fat reduction to diet, exercise, or other interventions. The condition persists when breakdown signals (inflammation from VAT) outrun repair processes in adipose and muscle tissue.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **Statins** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin stimulates the growth hormone axis. In human trials this led to measurable reductions in visceral adipose tissue. If visceral fat contributes to your lipid or inflammatory burden while on statins, lowering that depot may reduce the metabolic load that statins alone do not touch. The pathway is indirect: less VAT often correlates with improved triglyceride and total cholesterol readings in the same studies.\n\nIf muscle recovery or lean mass maintenance matters alongside statin use, the same GH-axis stimulation preserved or slightly increased lean body mass in trial participants without worsening glucose control. This differs from simple suppression of cholesterol production.\n\n## Why Statins matters for you\n\n**Drug:** Statins\n\n**What it does:** Lipid management; debated cognitive/muscle side effects in subset.\n\n**Therefore for you:** Statins reduce mechanical and inflammatory load on arteries by lowering circulating lipids. This supports cardiovascular stability but does not directly repair or reduce visceral fat stores. Any muscle side effects in sensitive users represent a potential trade-off against tissue repair pathways, making compounds that act on the GH axis a separate layer to consider rather than a replacement.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nTesamorelin addresses the visceral fat layer that statins leave untouched. Statins handle hepatic cholesterol output. Together they operate on distinct but overlapping metabolic compartments: one reduces production signals in the liver, the other reduces the adipose source of free fatty acids and inflammation. The studies that measured lipids during tesamorelin use already included participants on lipid-lowering therapy, showing additive directional changes in triglycerides without major pharmacokinetic interference with simvastatin.\n\n## What the evidence actually shows\n\nHuman trials (multiple Phase 2/3, NEJM 2007, extension to 52 weeks, PLOS One 2017) consistently report 15–18% reductions in visceral adipose tissue measured by CT or MRI after 26–52 weeks of tesamorelin. Triglycerides fell 37–51 mg/dL and total cholesterol-to-HDL ratio improved modestly. These changes occurred in HIV patients with lipodystrophy, many already on antiretrovirals and some on statins. LDL and non-HDL cholesterol also declined in one 12-week diabetes cohort. No clinically meaningful worsening of glucose parameters appeared across trials.\n\nA pharmacokinetic study found only an 8% drop in simvastatin AUC when co-administered with tesamorelin, described as minimal impact on CYP3A activity. Statin use did not blunt the VAT reduction in at least one liver-fat trial.\n\nPr","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"Tesamorelin reduced visceral adipose tissue by 15.2% versus 5% increase with placebo in a 26-week randomized trial.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human trial endpoint linking GH-axis stimulation to VAT change relevant to metabolic load.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"Triglycerides decreased by 50 mg/dL with tesamorelin versus 9 mg/dL increase with placebo over 26 weeks.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Lipid outcome measured alongside VAT reduction in the same human cohort.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c4","text":"VAT and triglyceride reductions were sustained over 52 weeks in an open-label extension without worsening glucose parameters.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Longer-term human safety and efficacy data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"Co-administration of tesamorelin with simvastatin produced an 8% decrease in simvastatin AUC with minimal CYP3A impact.","tier":"human","weight":0.8,"section":"Why Statins matters for you","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Pharmacokinetic data in humans addressing potential interaction with common statin.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c5","text":"Public discussion of the tesamorelin-statin combination on Reddit and X is sparse and lacks detailed outcome reports.","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Search results show no substantive user anecdotes pairing the two.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18057338/","title":"Metabolic effects of a growth hormone-releasing factor in patients with HIV","quote":"Daily tesamorelin for 26 weeks decreased visceral fat and improved lipid profiles","summary":"NEJM 2007 randomized trial: 15.2% VAT reduction, triglyceride drop of 50 mg/dL.","claim_ids":["c1","c2"],"link_status":"ok","quote_status":"verified","hash":"af156be8b7588397bffc38e8aafeea61d51b013175aea7538404ca2b7e3c6802"},{"id":"s2","type":"pubmed","url":"https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.27","title":"Impact of Tesamorelin on CYP3A activity","quote":"multiple 2 mg doses of tesamorelin administered with simvastatin resulted in an 8% decrease in simvastatin AUC","summary":"Pharmacokinetic study showing minimal interaction.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"ac7b3f166f4721d1e740aa9ff922d3f6066cfaaad45dc2e6421406191c8189cb"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18690162/","title":"Long-term safety and effects of tesamorelin","quote":"sustained decreases in VAT and triglycerides over 52 weeks without aggravating glucose","summary":"52-week extension data.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"905340b4f3cde84d569c49b58d6aa99662a1e29a39c4f1f7500a9107c4ea095c"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/PeterAttia/comments/1u6ol0c/statins_insulin_and_inflammation/","title":"statins insulin and inflammation","quote":"Tesamorelin for fat loss and build muscle.","summary":"Isolated unrelated mention; no paired outcome reports found.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"29e53d47f711885f93f5e27c3963eab948a9889cfe2f237d3d64f828339b0cf5"}],"anecdotal_sources":[{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/PeterAttia/comments/1u6ol0c/statins_insulin_and_inflammation/","title":"statins insulin and inflammation","quote":"Tesamorelin for fat loss and build muscle.","summary":"Isolated unrelated mention; no paired outcome reports found.","claim_ids":["c5"],"link_status":"ok","quote_status":"unverified","hash":"29e53d47f711885f93f5e27c3963eab948a9889cfe2f237d3d64f828339b0cf5"}],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18057338/","title":"Metabolic effects of a growth hormone-releasing factor in patients with HIV","quote":"Daily tesamorelin for 26 weeks decreased visceral fat and improved lipid profiles","summary":"NEJM 2007 randomized trial: 15.2% VAT reduction, triglyceride drop of 50 mg/dL.","claim_ids":["c1","c2"],"link_status":"ok","quote_status":"verified","hash":"af156be8b7588397bffc38e8aafeea61d51b013175aea7538404ca2b7e3c6802"},{"id":"s2","type":"pubmed","url":"https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.27","title":"Impact of Tesamorelin on CYP3A activity","quote":"multiple 2 mg doses of tesamorelin administered with simvastatin resulted in an 8% decrease in simvastatin AUC","summary":"Pharmacokinetic study showing minimal interaction.","claim_ids":["c3"],"link_status":"ok","quote_status":"unverified","hash":"ac7b3f166f4721d1e740aa9ff922d3f6066cfaaad45dc2e6421406191c8189cb"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18690162/","title":"Long-term safety and effects of tesamorelin","quote":"sustained decreases in VAT and triglycerides over 52 weeks without aggravating glucose","summary":"52-week extension data.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"905340b4f3cde84d569c49b58d6aa99662a1e29a39c4f1f7500a9107c4ea095c"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"tesamorelin-statins","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":4,"anecdotal":1,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}